- Home
- HBCP vs ESPR Comparison
HBCP vs ESPR Comparison
Compare HBCP & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBCP
- ESPR
- Stock Information
- Founded
- HBCP 1908
- ESPR 2008
- Country
- HBCP United States
- ESPR United States
- Employees
- HBCP N/A
- ESPR N/A
- Industry
- HBCP Banks
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- HBCP Finance
- ESPR Health Care
- Exchange
- HBCP Nasdaq
- ESPR Nasdaq
- Market Cap
- HBCP 390.6M
- ESPR 410.2M
- IPO Year
- HBCP 2008
- ESPR 2013
- Fundamental
- Price
- HBCP $51.83
- ESPR $1.89
- Analyst Decision
- HBCP Buy
- ESPR Buy
- Analyst Count
- HBCP 1
- ESPR 6
- Target Price
- HBCP $50.00
- ESPR $7.25
- AVG Volume (30 Days)
- HBCP 23.4K
- ESPR 5.1M
- Earning Date
- HBCP 01-27-2025
- ESPR 02-25-2025
- Dividend Yield
- HBCP 2.02%
- ESPR N/A
- EPS Growth
- HBCP N/A
- ESPR N/A
- EPS
- HBCP 4.51
- ESPR N/A
- Revenue
- HBCP $130,219,000.00
- ESPR $295,451,000.00
- Revenue This Year
- HBCP N/A
- ESPR $186.04
- Revenue Next Year
- HBCP $4.77
- ESPR $11.25
- P/E Ratio
- HBCP $11.11
- ESPR N/A
- Revenue Growth
- HBCP N/A
- ESPR 187.12
- 52 Week Low
- HBCP $33.30
- ESPR $1.58
- 52 Week High
- HBCP $52.39
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- HBCP 68.50
- ESPR 39.38
- Support Level
- HBCP $48.97
- ESPR $1.71
- Resistance Level
- HBCP $51.00
- ESPR $2.26
- Average True Range (ATR)
- HBCP 1.34
- ESPR 0.14
- MACD
- HBCP 0.61
- ESPR -0.01
- Stochastic Oscillator
- HBCP 100.00
- ESPR 33.33
About HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans. Its primary expenses are interest expense on deposits and borrowings and general operating expenses.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.